Table 1 Baseline demographics, risk factors, and clinical measures, by country.
| Variable | Country | Total | p Value | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belgium | Canada | Denmark | Finland | France | Germany | Ireland | Nether lands | Norway | Sweden | UK | ||||||||||||||||
| No of subjects | 40 | 388 | 110 | 27 | 191 | 36 | 61 | 143 | 82 | 123 | 283 | 1484 | ||||||||||||||
| Centres | 4 | 27 | 6 | 4 | 18 | 4 | 4 | 6 | 5 | 7 | 15 | 100 | ||||||||||||||
| Age (y) | 72.8 (8.8) | 70.8 (11.2) | 72.4 (11.7) | 69.6 (10.6) | 70.1 (12.4) | 70.7 (10.3) | 70.3 (12.1) | 71.8 (10.8) | 75.3 (7.9) | 74.8 (8.1) | 71.1 (11.0) | 71.6 (11.0) | 0.0012 | |||||||||||||
| Sex (male, %) | 22 (55.0) | 218 (56.2) | 58 (52.7) | 16 (59.3) | 113 (59.2) | 19 (52.8) | 33 (54.1) | 67 (46.9) | 48 (58.5) | 68 (55.3) | 145 (51.2) | 807 (54.4) | 0.66 | |||||||||||||
| Race, white (%) | 40 (100) | 356 (91.8) | 110 (100) | 27 (100) | 186 (97.4) | 36 (100) | 61 (100) | 139 (97.2) | 82 (100) | 123 (100) | 269 (95.1) | 1429 (96.3) | 0.0002 | |||||||||||||
| Current smoking (%) | 11 (27.5) | 116 (29.9) | 50 (45.5) | 4 (14.8) | 27 (14.1) | 6 (16.7) | 18 (29.5) | 35 (24.5) | 20 (24.4) | 20 (16.3) | 75 (26.5) | 382 (25.7) | <0.0001 | |||||||||||||
| Previous HT (%) | 27 (67.5) | 225 (58.0) | 38 (34.5) | 14 (51.9) | 100 (52.4) | 22 (61.1) | 33 (54.1) | 68 (47.6) | 27 (32.9) | 54 (43.9) | 119 (42.0) | 727 (49.0) | <0.0001 | |||||||||||||
| Previous DM (%) | 7 (17.5) | 97 (25.0) | 17 (15.5) | 6 (22.2) | 35 (18.3) | 5 (13.9) | 6 (9.8) | 20 (14.0) | 7 (8.5) | 18 (14.6) | 32 (11.3) | 250 (16.8) | 0.0002 | |||||||||||||
| Previous MI (%) | 5 (12.5) | 90 (23.2) | 12 (10.9) | 6 (22.2) | 12 (6.3) | 2 (5.6) | 8 (13.1) | 15 (10.5) | 14 (17.1) | 22 (17.9) | 46 (16.3) | 232 (15.6) | <0.0001 | |||||||||||||
| Previous stroke (%) | 5 (12.5) | 58 (15.9) | 11 (10.0) | 2 (7.4) | 10 (5.2) | 5 (13.9) | 7 (11.5) | 18 (12.6) | 12 (14.6) | 17 (13.8) | 48 (17.0) | 193 (13.0) | 0.06 | |||||||||||||
| Premorbid mRS ( = 0, %) | 24 (60.0) | 295 (76.0) | 63 (57.3) | 22 (81.5) | 169 (88.5) | 26 (72.2) | 39 (63.9) | 104 (72.7) | 55 (67.1) | 76 (61.8) | 179 (63.3) | 1052 (70.9) | <0.0001 | |||||||||||||
| OCSP type (TACI, %) | 25 (62.5) | 97 (25.0) | 21 (19.1) | 17 (63.0) | 65 (34.0) | 1 (2.8) | 34 (55.7) | 66 (46.2) | 25 (30.5) | 52 (42.3) | 119 (42.0) | 522 (35.2) | <0.0001 | |||||||||||||
| SSS | 30.3 (12.8) | 34.8 (12.4) | 36 (11.8) | 31.9 (13.1) | 29.4 (13.7) | 36.1 (11.6) | 28.6 (11.8) | 30.4 (12.3) | 35.5 (10.0) | 32.5 (13.1) | 30.0 (13.1) | 32.3 (12.8) | <0.0001 | |||||||||||||
| SBP (mm Hg) | 152.2 (19.6) | 153.8 (21.9) | 162.8 (24.2) | 154.7 (18.6) | 157.0 (23.5) | 159.2 (19.0) | 155.2 (20.0) | 157.8 (23.7) | 157.2 (19.9) | 163.3 (21.0) | 153.0 (23.0) | 156.2 (22.4) | 0.0001 | |||||||||||||
| AF on ECG (%) | 1 (2.5) | 26 (6.7) | 10 (9.1) | 0 (0) | 18 (9.4) | 3 (8.3) | 16 (26.2) | 16 (11.2) | 8 (9.8) | 31 (25.2) | 52 (18.4) | 181 (12.2) | <0.0001 | |||||||||||||
| Infarct on CT (%) | 14 (35.0) | 230 (59.3) | 76 (69.1) | 21 (77.8) | 91 (47.6) | 26 (72.2) | 38 (62.3) | 78 (54.5) | 41 (50.0) | 81 (65.9) | 201 (71.0) | 897 (60.4) | <0.0001 | |||||||||||||
| Time to randomisation (h) | 24.2 (13.0) | 25.8 (13.1) | 28.6 (12.9) | 28.9 (13.4) | 21.7 (12.9) | 16.1 (9.8) | 31.1 (11.4) | 22.3 (11.9) | 28.7 (11.9) | 24.4 (11.7) | 30.6 (13.6) | 26.1 (13.2) | <0.0001 | |||||||||||||
Values are mean (SD) or frequency (%); comparison by χ2 test or Kruskal–Wallis test.
AF, atrial fibrillation; CT, computed tomography; DM, diabetes mellitus; HT, hypertension; MI, myocardial infarction; mRS, modified Rankin Scale; OCSP, Oxford Community Stroke Project; SBP, systolic blood pressure; SSS, Scandinavian Stroke Scale (range 0–58); TACI, total anterior circulation infarction.